59 results about "Uremic toxins" patented technology

A method of sorbent dialysis is provided for enhanced removal of uremic toxins, such as toxic anions and / or organic solutes, from spent dialysate. More highly adsorbable zirconium polymeric complexes of these anions and / or organic solutes can be initially formed in spent dialysate by treatment with zirconium salt solution or other zirconium cation source, and then removed with adsorbent to provide purified or regenerated dialysate. Sorbent dialysis systems for detoxifying spent dialysate containing toxic anions and organic solutes are also provided.

A method as well as an apparatus is disclosed for determining the efficiency of a currently performed kidney replacement therapy on the dialysis side making use of a dialysis machine which in a first step is operated in a hemodialysis or hemodiafiltration process and in a second step is sequentially changed over to a hemofiltration process or is changed over to a sequential mode in which merely a flow from the blood compartment via the semipermeable membrane to the dialysis fluid compartment of the dialyser is generated in which, according to a third step, a sensor for determining or measuring the concentration at least of uremic toxins in the saturated dialysate or ultra-filtrate which is connected downstream of a dialyser on the dialysis side outputs corresponding measuring signals that are representative of the current concentration at least of uremic toxins in the blood to a calculation or determination unit.

Methods and apparatus are disclosed for determining a substance in a fluid excreted / extracted from the body or spent dialysate, e.g., for determining a quality measure for the dialysis, such as the concentration of selected toxic substances, and / or for determining a removed total quantity of uremic toxins during a dialysis with a dialysis apparatus. A concentration of a substance in the fluid may be determined by: detecting, by an absorption sensor, a first extinction signal of the fluid at an analysis wavelength at a defined first pH value of the fluid; adjusting, by a pH adjusting device, a second pH value of the fluid which differs from the first pH value; detecting, by the absorption sensor, a second extinction signal of the fluid at the analysis wavelength at the second pH value; and processing / comparing the two extinction signals for the first and the second pH values and determining an absolute concentration of the substance dissolved in the fluid.

A sorbent dialysis cartridge is provided for removal of uremic toxins from dialysate wherein the sorbent cartridges can use non-enzymatic urea-binding materials in place of urease. The cartridge can have a first sorbent layer loaded with a polymerizable urea complexing agent and a second sorbent layer loaded with a crosslinker. The crosslinker can be crosslinkable with a soluble urea complex reaction product of the polymerizable urea complexing agent and urea when passing through the first sorbent layer to form a crosslinked polymeric urea complex which is attachable to the second sorbent layer. In another option, a sorbent layer can be used which has an insolubilized crosslinked polymeric urea-bindable complex attached thereto, wherein the crosslinked polymeric urea-bindable complex can be a reaction product of a crosslinker and polymerizable urea complexing agent. Methods and sorbent dialysis systems using the cartridge, and methods of making the sorbent material, are provided.

Provided is a temperature-based dialysate regeneration device for regulating a temperature of dialysate discharged from a hemodialyzer to remove uremic toxins and waste therefrom, the temperature-based dialysate regeneration device including: a Joule-Thomson refrigerator, including a compressor, condenser, expander and evaporator, an adsorbent column, and a dialysate heat exchanger in which heat transfer occurs between dialysates. The refrigerant used for the JT refrigerator may be a mixture of two or more refrigerants to enhance the heat transfer generated by the latent heat in the evaporator and the condenser.

The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and / or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. The oral delivery composition may be able to deliver the uremic toxin-treating enzymes, substantially undigested, to the intestines, where the enzymes can interact with uremic toxins transported to the intestines from the bloodstream. In another aspect, the treatment includes an oral delivery composition comprising a cell able to reduce the concentration of one or more uremic toxins in vivo. In some cases, the cell may be designed to overexpress one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase, for example, by transfecting the cell with a corresponding gene. In some embodiments, a species able to react with or otherwise sequester by-products of the uremic toxin-treating enzyme reactions may be included with the oral delivery composition. For example, if the by-product is ammonium, the species may be a sorbent able to adsorb ammonium, an enzyme able to react with the ammonium, or the like.

A device for extracorporeal blood treatment is disclosed that includes a detection equipment for detecting uremic toxins in a used dialysis liquid by measuring the absorbance, the detection equipment being provided at such a position downstream the outflow of the dialysis liquid from a filter element that at least one of the following requirements is fulfilled: a) the filling volume of the fluid line and of the components starting from the outflow of the used dialysis liquid from the filter element to the detection equipment is less than or equal to 100 ml; and b) the length of the fluid line starting from the outflow of the used dialysis liquid from the filter element to the detection equipment is at most 250 cm.

A hemocompatible adsorber for separating protein-bound uremic toxins contained in the blood of a patient and having a molecular mass of <500 g / mol regarding their carrier proteins, to adsorb the uremic toxins during hemodialysis. The hemocompatible adsorber including a polymer based on a cyclic oligosaccharide or a derivative thereof which is disposed on a solid carrier component. A device for hemodiafiltration including an extracorporeal circuit for receiving blood to be purified and a hemodialyzer connected to the blood circulation of a patient, wherein a hemocompatible adsorber is provided for separating protein-bound uremic toxins contained in the blood of a patient and having a molecular mass of <500 g / mol regarding their carrier proteins. The hemocompatible adsorber, which is disposed on a solid carrier component in at least one layer on the blood side within the hemodialyzer, includes a polymer based on a cyclic oligosaccharide or a derivative thereof.

Whole blood is treated extracorporeally to remove substances contrary to health using mesoporous / microporous or macroporopus / microporous carbon in the form of beads or a channel monolith. The carbon may be the result of carbonizing a mesoporous or macroporous phenolic resin. Substances contrary to health include externally introduced toxins such as bacterially derived staphylococcus enterotoxins A, B, TSST-1 or autologous, biologically active molecules with harmful, systemic effects when their activity is excessive or unregulated. Examples include the removal of inappropriate amounts of pro- or anti-inflammatory molecules and toxic mediators of systemic inflammatory response syndrome related to sepsis, cardio-pulmonary by-pass surgery, ischaemic reperfusion injury; the removal of larger molecular weight and protein bound uremic toxins related to kidney and hepatic toxins related to liver failure and the removal of toxins relevant to biological and chemical warfare.